Gracell Bio

formerly Gracell BiotechnologiesAcquired

Gracell Bio is a biotech company in Shanghai, China, founded in 2017. It has raised $150.0M across 1 round, most recently a $150.0M Private Equity in August 2023.

Pioneering Next Generation CAR-T Therapies

Headquarters
Shanghai, Shanghai
Employees
11–50
Founded
2017
Business Model
B2B
Total Funding
$150.0M
Last Round
$150.0M Private EquityAug 2023
Rounds
1
Acquisition Date
Dec 2023

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 1 funding round and 3 investors for this company. The full record is or through the API.

About

Gracell is a global clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cell therapies that address major industry challenges and unmet medical needs in cancer and autoimmune disease. It aims to disrupt conventional CAR-T approaches with its FasTCAR and TruUCAR technology platforms and SMART CART module. FasTCAR uses next-day manufacturing to generate younger, less exhausted CAR-T cells, TruUCAR explores off-the-shelf allogeneic therapies, and SMART CART is designed to tackle solid tumors.

Summary

It lists 11–50 employees. It has raised $150.0M in total across 1 round, most recently a $150.0M Private Equity round in Aug 2023. Investors include AstraZeneca, Vivo Capital and Pivotal Life Sciences.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Data from Indexed.vcUpdated
AcquisitionDec 2023

Sign up to see all 2 events

Funding: Private Equity. Amounts, valuations, and investors where available.

Investors

Similar Companies

Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech, Life Sciences
Series CTotal funding$955.0MSep 2024
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech, Healthcare
Venture RoundTotal funding$884.0MJul 2025

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Gracell Bio on Indexed.vc
<a href="https://indexed.vc/companies/gracell-bio"><img src="https://indexed.vc/api/badge/company/gracell-bio" alt="Gracell Bio on Indexed.vc" width="260" height="76" /></a>